Abeona Therapeutics Inc. (ABEO) had a busy Monday. The biopharmaceutical company reported mixed third-quarter financial results, bolstered its rare disease pipeline through an asset acquisition, and secured $30 million in private placement funding.
The headline numbers were a bit of a split decision. Abeona posted an earnings loss of 8 cents per share, comfortably beating the estimated 15-cent loss. But quarterly revenue of $13.491 million came in below consensus projections of $16.484 million. So the company lost less money than expected while bringing in less revenue than Wall Street wanted.
A New Drug for a Difficult-to-Treat Esophageal Condition
Abeona also agreed to acquire APT-1011, now renamed ABO-801, from Ellodi Pharmaceuticals. The drug candidate targets eosinophilic esophagitis, a chronic inflammatory esophageal condition affecting approximately 360,000 individuals across the U.S.
The treatment is a once-daily oral disintegrating tablet that delivers fluticasone propionate directly across the esophagus. It holds U.S. Food and Drug Administration Orphan Drug designation.
The deal structure is worth a closer look. Abeona is paying no upfront cash. Instead, it issued $20 million in common shares to Ellodi. Ellodi also stands to receive $30 million upon regulatory approval, up to $30 million in commercial sales milestones, and tiered royalties.
Following encouraging endoscopic activity in earlier trials, Abeona plans to initiate a Phase 3 clinical trial in mid-2027, projecting topline results by late 2028. That is a long runway, but the company is clearly betting the drug can become a meaningful commercial asset.
Filling the Coffers and Building Commercial Momentum
To strengthen capital reserves, Abeona secured $30 million in private placement gross proceeds from institutional healthcare investors, including Nantahala Capital, Marshall Wace, and Perceptive Advisors.
The company issued 6.4 million shares at $3.75 each alongside pre-funded warrants for approximately 1.6 million shares. The proceeds will finance pipeline programs and commercial activities, with the company citing general corporate purposes, funding the development of its product candidate pipeline, and supporting commercialization efforts for ZEVASKYN.
Speaking of ZEVASKYN, commercial momentum accelerated. Third-quarter net product revenue rose 18% sequentially to $13.5 million. The company completed six patient treatments during the period, reaching 15 total treatments since launch.
There is also a reimbursement tailwind. New Technology Add-On Payment status took effect October 1, 2026, establishing supplemental Medicare reimbursement for qualifying hospitals. That matters because better reimbursement can smooth the path for adoption.
Abeona closed the quarter with $134.9 million in cash, cash equivalents, and short-term investments, excluding the subsequent private placement proceeds.
ABEO Price Action: Abeona Therapeutics shares were down 11.51% at $3.69 during premarket trading on Monday, according to market data.
